Hybrid closed-loop system

Hybrid closed-loop system has been studied in 3 papers since 2026: 1 trial and 1 observational study in people, 1 review; 3 in the past year. The newest paper, Oct 26, 2026: “Effects of hybrid closed-loop systems and SGLT2i on myocardial deformation and vascular function in type 1 diabetics”.

Intervention

3 papers study it7 findingsUpdated

1 new paper in 30 daysSee all 3 papers on hybrid closed-loop system

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“patients on Hybrid closed-loop systems showed a 2-fold and a 4-fold higher increase in time in range”
Effects of hybrid closed-loop systems and SGLT2i on myocardial deformation and vascular function in type 1 diabeticsESC Congress 2026 abstract2026doi:10.1093/eurheartj/ehag785.4196

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Funder: Hellenic Diabetes Association
  • 4 of 7 findings with company ties
  • Human trial1
  • Humans1

Studies in people

1 study gave hybrid closed-loop system to people and measured what changed.

What changedDesignPeopleSource

up: Increases time in range2-fold and 4-fold higher increase

down: Decreases pulse wave velocity-15.71% vs +5.67% (P < 0.05)

down: Decreases central systolic blood pressure-8.15% vs +1.49% (P < 0.05)

Trial12 months90 peoplePoorly controlled type 1 diabetesDiabetes technology & therapeutics, Feb 5, 2026

What did studies of hybrid closed-loop system find?

6

Studies of hybrid closed-loop system measured 6 outcomes, among them pulse wave velocity, global longitudinal strain and time in normal glucose range.

Pulse wave velocity

downin humans2

2 studies
  1. Hybrid closed-loop system decreases pulse wave velocity in humans (Poorly controlled type 1 diabetes; compared with intensified multiple daily injections) (-15.71% versus +5.67% with multiple daily injections; P<0.05).

    “Hybrid closed-loop systems and SGLT-2i group displayed the most significant decrease in PWV (-15.71% and -10.14%)”

    Human trialPoorly controlled type 1 diabetes; compared with intensified multiple daily injections12 months

    Effects of hybrid closed-loop systems and SGLT2i on myocardial deformation and vascular function in type 1 diabetics

    ESC Congress 2026 abstract

  2. Hybrid closed-loop system decreases pulse wave velocity in humans (poorly controlled type 1 diabetes) (-15.71% vs +5.67% (P < 0.05)).

    “At 12 months, HCLS and SGLT-2i group displayed the most significant decrease in PWV (-15.71% and -10.14%), cSBP (-8.15% and -6.88%), and PBR (-6.98% and -8.98%) compared with MDI”

    Human trialpoorly controlled type 1 diabetes12 months

    MiniMedTM 780G Hybrid Closed-Loop Systems Improves Markers of Vascular and Endothelial Function in Patients with Type 1 Diabetes: Association with Continuous Glucose Monitoring Metrics

    Diabetes technology & therapeutics

More on Pulse wave velocity

Global longitudinal strain

upin humans1

1 study
  1. Hybrid closed-loop system improves global longitudinal strain in humans (Poorly controlled type 1 diabetes; compared with intensified multiple daily injections) (6.7% improvement versus 2.2% with multiple daily injections; P<0.05).

    “Hybrid closed-loop systems and SGLT-2i group displayed the most significant improvement in GLS (6.7 % and 4 %)”

    Human trialPoorly controlled type 1 diabetes; compared with intensified multiple daily injectionsmyocardium12 months

    Effects of hybrid closed-loop systems and SGLT2i on myocardial deformation and vascular function in type 1 diabetics

    ESC Congress 2026 abstract

More on Global longitudinal strain

Time in normal glucose range

upin humans1

1 study
  1. Hybrid closed-loop system increases time in normal glucose range in humans (Poorly controlled type 1 diabetes; compared with intensified multiple daily injections) (4-fold higher increase than multiple daily injections; P <0.001).

    “patients on Hybrid closed-loop systems showed a 2-fold and a 4-fold higher increase in time in range”

    Human trialPoorly controlled type 1 diabetes; compared with intensified multiple daily injections12 months

    Effects of hybrid closed-loop systems and SGLT2i on myocardial deformation and vascular function in type 1 diabetics

    ESC Congress 2026 abstract

More on Time in normal glucose range

Perfused boundary region

downin humans1

1 study
  1. Hybrid closed-loop system decreases perfused boundary region in humans (poorly controlled type 1 diabetes) (-6.98% vs +1.99% (P < 0.05)).

    “At 12 months, HCLS and SGLT-2i group displayed the most significant decrease in PWV (-15.71% and -10.14%), cSBP (-8.15% and -6.88%), and PBR (-6.98% and -8.98%) compared with MDI”

    Human trialpoorly controlled type 1 diabetes12 months

    MiniMedTM 780G Hybrid Closed-Loop Systems Improves Markers of Vascular and Endothelial Function in Patients with Type 1 Diabetes: Association with Continuous Glucose Monitoring Metrics

    Diabetes technology & therapeutics

More on Perfused boundary region

Central systolic blood pressure

downin humans1

1 study
  1. Hybrid closed-loop system decreases central systolic blood pressure in humans (poorly controlled type 1 diabetes) (-8.15% vs +1.49% (P < 0.05)).

    “At 12 months, HCLS and SGLT-2i group displayed the most significant decrease in PWV (-15.71% and -10.14%), cSBP (-8.15% and -6.88%), and PBR (-6.98% and -8.98%) compared with MDI”

    Human trialpoorly controlled type 1 diabetes12 months

    MiniMedTM 780G Hybrid Closed-Loop Systems Improves Markers of Vascular and Endothelial Function in Patients with Type 1 Diabetes: Association with Continuous Glucose Monitoring Metrics

    Diabetes technology & therapeutics

More on Central systolic blood pressure

Time in range

upin humans1

1 study
  1. Hybrid closed-loop system increases time in range in humans (poorly controlled type 1 diabetes) (2-fold and 4-fold higher increase).

    “patients on HCLS showed a 2-fold and a 4-fold higher increase in TIR compared with SGLT-2i (P = 0.026) and MDI group (P < 0.001), respectively.”

    Human trialpoorly controlled type 1 diabetes12 months

    MiniMedTM 780G Hybrid Closed-Loop Systems Improves Markers of Vascular and Endothelial Function in Patients with Type 1 Diabetes: Association with Continuous Glucose Monitoring Metrics

    Diabetes technology & therapeutics

More on Time in range

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 2Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 03 papers in 12 months